OUR GROUP
An independent Group committed to therapeutic progress to serve patient needs
34th
LARGEST PHARMACEUTICAL
COMPANY WORLDWIDE
and 2nd largest pharmaceutical Group
in France*
150
COUNTRIES in which
the Group’s medicines
are distributed
100
MILLION PATIENTS
treated each day worldwide with
Group medicines.
21,900
EMPLOYEES
SERVIER, A Global Pharmaceutical Group
Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day.
A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France,and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle.
Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide.
Our Vocation
We are committed to therapeutic progress to serve patient needs.
Our Vision
Founded to serve health, our Group aspires to make a meaningful social impact for patients and for a sustainable world.
Our Values
DARE TO INNOVATE
CARE
GROW BY SHARING
COMMIT TO SUCCEED
1st
Leading Pharmaceutical Group in
Hypertension Worldwide
4.33/5
Overall Engagement Score Achieved by
the Servier Group
13
Production Sites
83%
of Employees Would Recommend Servier as a Great Place to Work
Source : annual engagement survey conducted
with the Gallup Institute – 2024 Group results
6th
Leading Pharmaceutical Group in
Cardiology Worldwide
Source: IQVIA, Analytics Link / World 82 countries – MAT Q1-2025
Research & Innovation
Our aim is clear—to pick up the pace of research and efforts to develop new therapeutic solutions guided by a long-term vision.
Day in, day out, our teams work tirelessly to discover and develop medicines where patient needs are greatest.
Servier’s governance model headed by a non-profit foundation aligns perfectly with the long-term perspective required for research and development. Our independence from market forces means we can invest heavily in R&D to innovate and develop new medicines.
That is why we invest over 20% of our sales revenue (excl. generic medicines) each year in R&D.
A comprehensive healthcare offering
Every day, Servier helps to treat patients in 150 countries using its extensive range of brand-name and generic medicines. In line with our conviction to offer a comprehensive range of health care solutions, we also provide e-health solutions that cover the entire patient journey.
SERVIER BRAND-NAME MEDICINES
GENERIC MEDICINES
Top 10
Servier makes it into the top 10
(of 46 companies) among patient
organizations working and/or familiar
with the Servier Group
1st
Ranked 1st out of 28 companies
by oncology patient
organizations
Source: PatientView Report
2024 on the reputation
of pharmaceutical companies
R&D Pipeline
36 projects in clinical development
(including 14 new
molecular entities)
and 24 research projects (June 2025)
Servier Research & Development Institute in Paris-Saclay
In Paris-Saclay, Servier develops a more agile and open approach to R&D that centers even more closely around the patient to speed up the discovery of innovative therapeutic solutions.
- 2023 – the research institute opens its doors
- Building spanning 45,000m 2
- 1,500 employees
A Partner of Choice
Our partnership strategy centers around a single objective to ramp up the speed with which we develop treatments that significantly improve patients’ quality of life. We take a people-oriented approach to our partnerships, and we focus on creating win-win situations by pooling our expertise.
We are keen to invest in innovation that benefits patients in the future.
A Strong Industrial Network
At our 13 production sites located throughout the world, we produce and distribute our medicines to the highest standards on quality, safety, and reliability.
By harnessing digital innovation across the entire value chain, we continue to enhance our agility to meet patient demand.
Making a Positive Impact on Society
The Group has adopted a proactive approach to Corporate Social Responsibility. This approach is structured around 4 CSR commitments that bring together 17 priority challenges, identified using a diagnosis based on ISO 26000 guidelines and interviews with stakeholders.
Since 2016, the Mécénat Servier Charity Fund has been supporting general interest initiatives in France and abroad in the fields of health care, education, culture and living together. More information: https://mecenat.servier.com/